Alnylam Pharmaceuticals Inc. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R...
Alnylam Pharmaceuticals, Inc. price and volume Combination chart with 2 data series. Chart represents Alnylam Pharmaceuticals, Inc. price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart has 2 Y axes displaying symbol price, and symbol volume.. Jan 2025...
Alnylam Pharmaceuticals, Inc.ALNYannounced that licensee Vir Biotechnology, Inc. has initiated a phase I/II study evaluating VIR-2218 for the treatment of chronic hepatitis B virus (HBV) infection. VIR-2218 is a novel, investigational RNA interference (RNAi) therapeutic that is administered via ...
ALNYLAM PHARMACEUTICALS, INC. 4,736,842 Shares of Common Stock Underwriting Agreement filed by Alnylam Pharmaceuticals, Inc. on January 26th, 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 31, 2024--Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter endedSeptember 30, 2024and reviewed recent business highlights. ...
ALNYLAM PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share amounts) June 30, 2024 December 31, 2023 ASSETS (Unaudited) Current assets: Cash and cash equivalents $ 968,492 $ 812,688 Marketable debt securities 1,646,268 1,615,516 Marketable eq...
Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock quote as well as historical stock price data.
Net loss per common share — basic and diluted $ (2.16 ) $ (2.09 ) $ (7.20 ) $ (7.46 ) Weighted-average common shares used to compute basic and diluted net loss per common share 119,773 116,274 118,451 114,986 ...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2021 and reviewed recent business highlights. "2021 was another remarkable yea
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter